Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sage Therapeutics Raises US$38 Million In Series C Venture Financing 11
Sage Therapeutics Raises US$10 Million In Venture Financing 13
Sage Therapeutics Raises US$20 Million In Series B Venture Financing 14
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round 15
Partnerships 16
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 16
Licensing Agreements 17
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 17
Sage Therapeutics Enters into Licensing Agreement with University of California 18
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 19
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 20
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 21
Equity Offering 22
Sage Therapeutics Raises USD575 Million in Public Offering of Shares 22
Sage Therapeutics Raises USD345 Million in Public Offering of Shares 24
Sage Therapeutics Raises USD201 Million in Public Offering of Shares 26
Sage Therapeutics Raises USD150 Million in Public Offering of Shares 28
Sage Therapeutics Raises USD138 Million in Public Offering of Shares 30
Sage Therapeutics Raises USD103.5 Million in IPO 32
Sage Therapeutics Inc – Key Competitors 34
Sage Therapeutics Inc – Key Employees 35
Sage Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 07, 2018: Sage therapeutics announces second quarter 2018 financial results and highlights pipeline and business progress 37
May 03, 2018: Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness 39
Feb 22, 2018: Sage Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 42
Nov 02, 2017: Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update 45
Aug 03, 2017: Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update 48
May 09, 2017: Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update 50
Feb 23, 2017: Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 53
Corporate Communications 56
Nov 08, 2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors 56
Jul 10, 2017: Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 57
Apr 24, 2017: Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team 58
Product News 59
04/19/2017: Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting 59
02/07/2018: Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder 60
01/31/2018: Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders 61
Product Approvals 63
May 30, 2018: Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression 63
Apr 23, 2018: Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression 64
May 18, 2017: Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder 65
Clinical Trials 66
Jun 12, 2018: Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting 66
Apr 17, 2018: Sage Therapeutics to Present Brexanolone Postpartum Depression Data at Upcoming Spring Medical Meetings 67
Apr 17, 2018: Sage Therapeutics to Present SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings 68
Dec 07, 2017: Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder 69
Nov 09, 2017: Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression 71
Sep 12, 2017: Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus 73
Jul 11, 2017: Alzheimer’s Drug Discovery Foundation announces new grant for an innovative Allopregnanolone clinical trial 74
Jun 12, 2017: Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression 75
Apr 19, 2017: Sage Therapeutics to Present on SAGE-217 at American Academy of Neurology 2017 Annual Meeting 76
Feb 13, 2017: Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder 77
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sage Therapeutics Raises US$38 Million In Series C Venture Financing 11
Sage Therapeutics Raises US$10 Million In Venture Financing 13
Sage Therapeutics Raises US$20 Million In Series B Venture Financing 14
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round 15
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 16
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 17
Sage Therapeutics Enters into Licensing Agreement with University of California 18
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 19
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 20
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 21
Sage Therapeutics Raises USD575 Million in Public Offering of Shares 22
Sage Therapeutics Raises USD345 Million in Public Offering of Shares 24
Sage Therapeutics Raises USD201 Million in Public Offering of Shares 26
Sage Therapeutics Raises USD150 Million in Public Offering of Shares 28
Sage Therapeutics Raises USD138 Million in Public Offering of Shares 30
Sage Therapeutics Raises USD103.5 Million in IPO 32
Sage Therapeutics Inc, Key Competitors 34
Sage Therapeutics Inc, Key Employees 35
Sage Therapeutics Inc, Subsidiaries 36
List of Figures
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9